RW-2016 - Fat Emulsions and Protein Delivery to the Critically Ill Patient

Jan 16, 2016 8:30am ‐ Jan 16, 2016 5:00pm

Objectives:

Summarize the potential utility of new high-resolution lipidomics/metabolomics in personalized medicine and biomarker development in critical care
Describe the impact of omega-3-fatty acids on endogenous lipid mediators relevant to infection and inflammation
Outline the impact of different IV fat emulsions on whole body metabolic pathways and cellular/organ structure and function (e.g. in gut, liver)
Explain the clinical research basis behind the development as well as current clinical utilization of the various different IV fat emulsions, strengths and limitations of existing clinical research, and needed directions for future clinical research
Evaluate the current IV fat emulsion administration guidelines and what research is needed to solidify these going forward
Evaluate the current basic science and clinical studies dealing with protein delivery in critically ill patient
Summarize the influence on exogenous protein administration on whole body protein kinetics and stress response pathways in critically ill patients
Assess, monitor, and identify patients with low skeletal muscle mass and the influence of exogenous protein on muscle mass
Outline how muscle mass influences functional recovery and the influence of protein administration on functional recovery
List key methodological and practical issues in designed protein dosing studies in critically ill patients

Bruce Bistrian, MD, PhD
Doug G. Burrin, PhD, Professor of Pediatrics, Baylor College of Medicine; Research Physiologist, U.S. Department of Agriculture - Agricultural Research Service, Children’s Nutrition Research Center, Houston, TX
Daren K. Heyland, MD, Professor of Medicine, Queen’s University, Kingston, Ontario, Canada
Marina Mourtzakis, PhD, BSc, Bkin, Associate Professor, Kinesiology, Department of Kinesiology, University of Waterloo, Waterloo, ON, Canada
Olav Rooijackers, PhD, Professor, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden
Douglas Seidner, MD, AGAF, FACG, FASPEN, CNSC, Associate Professor of Medicine, Division of Gastroenterology, Hepatology and Nutrition; Director, Vanderbilt Center for Human Nutrition, Vanderbilt School of Medicine, Nashville, TN
Thomas R. Ziegler, MD, Professor of Medicine, Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA

Philip C. Calder, BSc(Hons), PhD, DPhil, RNutr, FSB, FAfN, Professor of Nutritional Immunology, University of Southampton, Southampton, United Kingdom
Renee D. Stapleton, MD, PhD, Associate Professor, University of Vermont Medical Center, Burlington, VT